Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Knight Therapeutics Inc. (GUD.TO)
Montreal, QC, CA
Knight Therapeutics Inc., a specialty pharmaceutical enterprise established in Montreal, Canada in 2013, operates globally, with a strong presence across Canada and Latin America. The company's core business revolves around the development, acquisition, in-licensing, out-licensing, promotion, and distribution of a diverse portfolio encompassing pharmaceutical products, consumer health goods, and medical devices. Its extensive product catalog features treatments such as Nerlynx, prescribed for extended adjuvant and metastatic breast cancer; Tafasitamab, used for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib, targeting metastatic cholangiocarcinoma; Trelstar, addressing advanced prostate cancer and pain associated with endometriosis; Vidaza, indicated for myelodysplastic syndrome; Abraxane, for metastatic pancreatic adenocarcinoma; Halaven, for metastatic breast cancer and soft tissue sarcoma; and Lenvima, useful in differentiated thyroid cancer, advanced renal cell cancer, and unresectable hepatocellular carcinoma. The company's offerings further include Ladevina, for multiple myeloma, myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix, for metastatic prostate cancer; Karfib, for relapsed or refractory multiple myeloma; Leprid, for advanced prostate cancer; and Rembre, for chronic myeloid leukemia. For infectious diseases, it provides Ambisome and Cresemba for fungal infections, along with Impavido for leishmaniasis. Other notable products include Exelon, managing mild to moderately severe dementia; Ibsrela, for irritable bowel syndrome with constipation; Salofalk, for ulcerative colitis; Ursofalk, to treat biliary cirrhosis; Imvexxy, for moderate to severe dyspareunia; Bijuva, for moderate to severe vasomotor symptoms linked to menopause in women with intact uteri; Fibridoner, for idiopathic pulmonary fibrosis; Toliscrin DPI, addressing pseudomonas aeruginosa lung infection in patients with cystic fibrosis; Toliscrin 1-2, for severe acute or resistant chronic infections; and Tobradosa Haler, for chronic lung infections. Beyond its product-focused endeavors, Knight Therapeutics Inc. also provides financing to other life science companies and makes strategic investments in life sciences venture capital funds.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.35% | +8.25% | +14.70% | +45.06% | +38.78% | +43.14% | +47.78% | +78.19% | +64.33% | +6.26% | +126.11% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 3 | 0 |
| Buy | 3 | +1 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+21.2% ★ Q1'26: +68.5% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-226.2% Q1'26: +496.3% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+10.1% ★ Q1'26: +25.0% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-0.5% Q1'26: +7.1% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-0.3% Q1'26: +5.4% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-1.8% ★ Q1'26: -1.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×1.43× ★ Q1'26: 0.65× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 5 Rev. Ana. 2 EPS Ana. |
Dec 2027 5 Rev. Ana. 2 EPS Ana. |
Dec 2028 3 Rev. Ana. 2 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
365.3K
est: 358.8K (+1.8%)
|
1.04M
est: 1.18M (-12.0%)
|
5.94M
est: 5.52M (+7.6%)
|
8.63M
est: 8.30M (+4.0%)
|
12.50M
est: 11.29M (+10.7%)
|
47.46M
est: 41.93M (+13.2%)
|
199.52M
est: 192.49M (+3.7%)
|
243.48M
est: 247.00M (-1.4%)
|
293.56M
est: 274.63M (+6.9%)
|
328.20M
est: 337.87M (-2.9%)
|
371.30M
est: 361.56M (+2.7%)
|
450.09M
est: 435.53M (+3.3%)
|
510.08M
502.91M – 514.09M
+17.1% YoY
|
523.99M
500.20M – 546.97M
+2.7% YoY
|
545.75M
545.49M – 546.01M
+4.2% YoY
|
583.99M
566.60M – 599.11M
+7.0% YoY
|
609.65M
591.50M – 625.44M
+4.4% YoY
|
| EBITDA |
131.16M
est: 64.4K (+203,530.3%)
|
-11.18M
est: 211.5K (-5,389.0%)
|
-7.40M
est: 990.7K (-846.8%)
|
-7.28M
est: 1.49M (-588.3%)
|
-3.85M
est: 2.03M (-290.0%)
|
27.16M
est: 7.53M (+260.9%)
|
67.56M
est: 34.56M (+95.5%)
|
42.59M
est: 44.34M (-3.9%)
|
25.26M
est: 49.30M (-48.8%)
|
40.90M
est: 45.94M (-11.0%)
|
64.38M
est: 49.16M (+31.0%)
|
54.37M
est: 59.21M (-8.2%)
|
69.35M
68.37M – 69.89M
+17.1% YoY
|
71.24M
68.01M – 74.36M
+2.7% YoY
|
74.20M
74.16M – 74.23M
+4.2% YoY
|
79.40M
77.03M – 81.45M
+7.0% YoY
|
82.89M
80.42M – 85.03M
+4.4% YoY
|
| EBIT |
131.08M
est: 2.2K (+6,062,666.0%)
|
-11.31M
est: -12.54M (+9.8%)
|
-7.84M
est: 33.3K (-23,655.6%)
|
-8.91M
est: 50.0K (-17,895.6%)
|
29.46M
est: -14.39M (+304.7%)
|
23.15M
est: -19.90M (+216.4%)
|
35.48M
est: -92.26M (+138.5%)
|
10.31M
est: -106.25M (+109.7%)
|
-37.36M
est: -112.18M (+66.7%)
|
-9.50M
est: -10.31M (+7.9%)
|
11.28M
est: -69.95M (+116.1%)
|
-2.20M
est: -13.29M (+83.4%)
|
-15.57M
-15.69M – -15.35M
-17.1% YoY
|
-15.99M
-16.69M – -15.27M
-2.7% YoY
|
-16.66M
-16.66M – -16.65M
-4.2% YoY
|
-17.82M
-18.28M – -17.29M
-7.0% YoY
|
-18.61M
-19.09M – -18.05M
-4.4% YoY
|
| Net Income |
125.86M
|
34.17M
est: 343.25M (-90.0%)
|
18.56M
est: 189.61M (-90.2%)
|
17.24M
est: 27.90M (-38.2%)
|
24.08M
est: 23.58M (+2.1%)
|
14.52M
est: 82.84M (-82.5%)
|
31.76M
est: 78.51M (-59.5%)
|
15.68M
est: 90.42M (-82.7%)
|
-29.89M
est: -15.69M (-90.5%)
|
-16.84M
est: -20.45M (+17.7%)
|
4.33M
est: -5.06M (+185.6%)
|
-5.37M
est: -12.31M (+56.4%)
|
18.08M
17.42M – 18.73M
+246.8% YoY
|
20.86M
20.10M – 21.61M
+15.4% YoY
|
28.87M
25.67M – 32.08M
+38.4% YoY
|
30.87M
29.67M – 31.90M
+6.9% YoY
|
34.85M
33.50M – 36.02M
+12.9% YoY
|
| SGA |
4.28M
est: 107.9K (+3,871.5%)
|
9.09M
est: 354.1K (+2,466.1%)
|
9.83M
est: 1.66M (+492.8%)
|
11.58M
est: 2.50M (+363.9%)
|
12.06M
est: 3.39M (+255.3%)
|
32.25M
est: 12.60M (+155.9%)
|
74.43M
est: 131.05M (-43.2%)
|
74.38M
est: 150.91M (-50.7%)
|
88.62M
est: 159.34M (-44.4%)
|
83.69M
est: 94.97M (-11.9%)
|
99.35M
est: 183.22M (-45.8%)
|
123.96M
est: 122.41M (+1.3%)
|
143.37M
141.35M – 144.50M
+17.1% YoY
|
147.28M
140.59M – 153.74M
+2.7% YoY
|
153.39M
153.32M – 153.47M
+4.2% YoY
|
164.14M
159.26M – 168.39M
+7.0% YoY
|
171.35M
166.25M – 175.79M
+4.4% YoY
|
| EPS |
1.36
|
0.36
est: 0.31 (+15.7%)
|
0.15
est: 0.13 (+17.4%)
|
0.12
est: 0.12 (-1.6%)
|
0.17
est: 0.19 (-11.1%)
|
0.10
est: 0.18 (-44.0%)
|
0.24
est: 0.24 (+1.4%)
|
0.13
est: 0.20 (-35.0%)
|
-0.26
est: -0.19 (-36.8%)
|
-0.16
est: -0.21 (+22.3%)
|
0.04
est: -0.05 (+183.9%)
|
-0.05
est: -0.12 (+56.5%)
|
0.18
0.17 – 0.19
+246.8% YoY
|
0.21
0.20 – 0.22
+15.4% YoY
|
0.29
0.26 – 0.32
+38.1% YoY
|
0.31
0.30 – 0.32
+6.9% YoY
|
0.35
0.34 – 0.36
+12.9% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | B- | 2/5 | 1/5 | 2/5 | 3/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-07 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-06 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-05 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-04 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares S&P/TSX SmallCap Index ETF XCS.TO | 0.20% | 334.1K | 0.60% |
| 2 | State Street SPDR S&P International Small Cap ETF GWX | 0.07% | 581.3K | 0.40% |
| 3 | Dimensional - International Small Cap Value ETF DISV | 0.05% | 2.18M | 0.42% |
| 4 | Dimensional - International Small Cap ETF DFIS | 0.02% | 983.9K | 0.39% |
| 5 | Dimensional - International Vector Equity ETF DXIV | 0.01% | 25.7K | 0.53% |
| 6 | Dimensional - International Core Equity 2 ETF DFIC | 0.01% | 744.9K | 0.22% |
| 7 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 435.1K | 0.28% |
| 8 | Dimensional - International Core Equity Market ETF DFAI | 0.00% | 170.6K | 0.18% |
| 9 | Avantis International Equity ETF AVDE | 0.00% | 141.2K | 0.23% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Samira Sakhia | President, Chief Executive Officer & Director | 1M | female |
| Arvind Utchanah | Chief Financial Officer | 1M | male |
| Amal Khouri | Chief Business Officer | 1M | female |
| Christine Poulin | General Manager of Canada | 789.2K | female |
| Jonathan Ross Goodman | Executive Chairman | 528.4K | male |
| Susan Caroline Emblem | Global Vice President of Human Resources | 482.4K | female |
| Monica Percario | Global Vice President of Regulatory & Quality | 480.6K | female |
| Henrique Dias | Global Vice President of Marketing | 479.8K | male |
| Leopoldo Bosano | Vice-President of Manufacturing & Operations | 478.9K | male |
| Melanie Groleau | Global Vice President of Medical & Clinical | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for GUD.TO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
